trialsTrialRecruiting

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

A phase 1/2 trial of BDC-4182 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Bolt Biotherapeutics, Inc., now recruiting.

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer is a phase 1/2 interventional study registered as NCT06921837 by Bolt Biotherapeutics, Inc., with 122 participants planned, started 2025-05-26 and due to reach its primary completion in 2027-05. Interventions recorded: BDC-4182.

Setting

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer

Phase

Phase 1/2

Sponsor

Bolt Biotherapeutics, Inc.

Registry

Enrolled

122

Connected

Similar pages

not linked directly; found by shared links

Trial
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
SL-28 for Advanced Solid Tumours
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Trial
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.

cancers

2

Gastric & gastro-oesophageal junction cancer Oesophageal cancer

drugs

1

Phase 2monoclonal antibody

Evidence strength18/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
122 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Sources & links

ClinicalTrials.gov NCT06921837

Tags

pipeline

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers

Products

BDC-4182